Cargando…
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883533/ https://www.ncbi.nlm.nih.gov/pubmed/33691380 http://dx.doi.org/10.3324/haematol.2020.265777 |
_version_ | 1784659950210908160 |
---|---|
author | Zapatka, Marc Tausch, Eugen Öztürk, Selcen Yosifov, Deyan Yordanov Seiffert, Martina Zenz, Thorsten Schneider, Christof Bloehdorn, Johannes Döhner, Hartmut Mertens, Daniel Lichter, Peter Stilgenbauer, Stephan |
author_facet | Zapatka, Marc Tausch, Eugen Öztürk, Selcen Yosifov, Deyan Yordanov Seiffert, Martina Zenz, Thorsten Schneider, Christof Bloehdorn, Johannes Döhner, Hartmut Mertens, Daniel Lichter, Peter Stilgenbauer, Stephan |
author_sort | Zapatka, Marc |
collection | PubMed |
description | Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency over time and assessing the underlying cancer cell fraction revealed highly distinct evolutionary patterns. Surprisingly, in long-term stable disease and in relapse after long-lasting clinical response to treatment, clonal shifts are minor. In contrast, in refractory disease major clonal shifts occur although there is little impact on leukemia cell counts. As this striking pattern in refractory cases is not linked to a strong contribution of known CLL driver genes, the evolution is mostly driven by treatment-induced selection of sub-clones, underlining the need for novel, non-genotoxic treatment regimens. |
format | Online Article Text |
id | pubmed-8883533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-88835332022-03-18 Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy Zapatka, Marc Tausch, Eugen Öztürk, Selcen Yosifov, Deyan Yordanov Seiffert, Martina Zenz, Thorsten Schneider, Christof Bloehdorn, Johannes Döhner, Hartmut Mertens, Daniel Lichter, Peter Stilgenbauer, Stephan Haematologica Article Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency over time and assessing the underlying cancer cell fraction revealed highly distinct evolutionary patterns. Surprisingly, in long-term stable disease and in relapse after long-lasting clinical response to treatment, clonal shifts are minor. In contrast, in refractory disease major clonal shifts occur although there is little impact on leukemia cell counts. As this striking pattern in refractory cases is not linked to a strong contribution of known CLL driver genes, the evolution is mostly driven by treatment-induced selection of sub-clones, underlining the need for novel, non-genotoxic treatment regimens. Fondazione Ferrata Storti 2021-03-11 /pmc/articles/PMC8883533/ /pubmed/33691380 http://dx.doi.org/10.3324/haematol.2020.265777 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article Zapatka, Marc Tausch, Eugen Öztürk, Selcen Yosifov, Deyan Yordanov Seiffert, Martina Zenz, Thorsten Schneider, Christof Bloehdorn, Johannes Döhner, Hartmut Mertens, Daniel Lichter, Peter Stilgenbauer, Stephan Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy |
title | Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy |
title_full | Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy |
title_fullStr | Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy |
title_full_unstemmed | Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy |
title_short | Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy |
title_sort | clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883533/ https://www.ncbi.nlm.nih.gov/pubmed/33691380 http://dx.doi.org/10.3324/haematol.2020.265777 |
work_keys_str_mv | AT zapatkamarc clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT tauscheugen clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT ozturkselcen clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT yosifovdeyanyordanov clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT seiffertmartina clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT zenzthorsten clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT schneiderchristof clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT bloehdornjohannes clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT dohnerhartmut clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT mertensdaniel clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT lichterpeter clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy AT stilgenbauerstephan clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy |